Pharmaceutical News

RSS

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

When Amy Sweat was 19 years old, while she was in the hospital recovering from surgery, she was diagnosed with Type 2 diabetes. Ms. Sweat was treated for her diabetes, first on oral drugs, then on increasingly larger doses of insulin, but the years went by and she never was able to achieve good blood sugar control.

6 Jul 2016

Regular marijuana use impacts the brain's natural response to rewards

Most people would get a little 'rush' out of the idea that they're about to win some money.

6 Jul 2016

Added benefit of idelalisib drug not proven for patients with CLL

Already in 2014, the German Institute for Quality and Efficiency in Health Care examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with chronic lymphocytic leukaemia (CLL).

6 Jul 2016

Zinc acetate lozenges may be effective in treating common cold

Zinc acetate lozenges may reduce the duration of the common cold by nearly 3 days, according to a recent analysis.

6 Jul 2016

New study identifies vitamin D deficiency among many Malaysian children with epilepsy

Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.

6 Jul 2016

Diabetes drug metformin could help reduce toxic acid levels linked to MSUD

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic disorder involving the dysfunction of an enzyme which breaks down three essential amino acids: leucine, isoleucine and valine.

6 Jul 2016

PREVAIL IV trial opens in Liberia for EVD survivors with persistent traces of Ebola virus RNA

The Partnership for Research on Ebola Virus in Liberia, a U.S.-Liberia joint Clinical Research Partnership, today announced the opening of PREVAIL IV, a treatment trial for men who have survived Ebola virus disease (EVD) but continue to have evidence of Ebola virus genetic material, RNA, in their semen.

6 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Self-monitoring or self-management of anticoagulation therapy can help reduce thromboembolic events

Patients on long-term anticoagulation therapy who test their own blood-clotting time from home and continue to be managed by their GP are significantly less likely to experience a thromboembolic event, according to Oxford University researchers.

6 Jul 2016

Alnylam reports new results from investigational RNAi therapeutic programs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, both investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of hereditary TTR-mediated amyloidosis (hATTR amyloidosis).

6 Jul 2016

Roche Diagnostics responds to HPV announcement

Roche Diagnostics welcomes the announcement by Public Health Minister, Jane Ellison, to introduce Human Papillomavirus (HPV) primary screening in England.

6 Jul 2016

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.

6 Jul 2016

Researchers demonstrate simple approach to prove how classes of new drugs work

A collaborative effort by cancer researchers at Cold Spring Harbor Laboratory and chemists at Boehringer Ingelheim, a pharmaceutical firm, has resulted in the identification of a new drug target in leukemia and creation of a candidate drug that hits the target.

6 Jul 2016

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition.

5 Jul 2016

Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

The German Institute for Quality and Efficiency in Health Care assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier assessment, just after the Act on the Reform of the Market for Medicinal Products had come into force.

5 Jul 2016

FDA approves Absorb GT1 BVS to treat coronary artery disease

The U.S. Food and Drug Administration today approved the first fully absorbable stent to treat coronary artery disease.

5 Jul 2016

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

Study provides insight into why individual mycobacteria respond differently to antibiotics

Tuberculosis is one of the most common infectious diseases in the world, infecting almost 10 million people each year. Treating the disease can be challenging and requires a combination of multiple antibiotics delivered over several months.

4 Jul 2016

Studies shed more light on relation between bacteria, immune system and antibiotics

Antibiotics and the immune system are the two forces that cope with bacterial infections. Now, two studies from Isabel Gordo's laboratory, at Instituto Gulbenkian de Ciência, show for the first time that resistance to antibiotics and to the immune system is interconnected in bacteria.

4 Jul 2016

Antihypertensives prescribed for older adults despite having low blood pressure, study shows

According to a new study in the journal Age and Ageing, a significant proportion of patients over 70 remain on antihypertensive medication despite having low blood pressure.

4 Jul 2016

Pharmaceutical News

Liraglutide drug lowers blood sugar levels in diabetic patients taking large doses of insulin

Regular marijuana use impacts the brain's natural response to rewards

Added benefit of idelalisib drug not proven for patients with CLL

Zinc acetate lozenges may be effective in treating common cold

New study identifies vitamin D deficiency among many Malaysian children with epilepsy

Diabetes drug metformin could help reduce toxic acid levels linked to MSUD

PREVAIL IV trial opens in Liberia for EVD survivors with persistent traces of Ebola virus RNA

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Self-monitoring or self-management of anticoagulation therapy can help reduce thromboembolic events

Alnylam reports new results from investigational RNAi therapeutic programs

Roche Diagnostics responds to HPV announcement

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Researchers demonstrate simple approach to prove how classes of new drugs work

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Ticagrelor drug shows minor added benefit for patients with history of myocardial infarction

FDA approves Absorb GT1 BVS to treat coronary artery disease

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Study provides insight into why individual mycobacteria respond differently to antibiotics

Studies shed more light on relation between bacteria, immune system and antibiotics

Antihypertensives prescribed for older adults despite having low blood pressure, study shows

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News